> "Most of the active projects are in exploratory or preclinical stages. However, 5 candidates have recently moved into clinical development, including mRNA-1273 (Moderna), Ad5-nCoV (CanSino Biologicals), INO-4800 (Inovio), LV-SMENP-DC and pathogen-specific aAPC (Shenzhen Geno-Immune Medical Institute). Notably, Moderna was able to start clinical testing of its mRNA-based vaccine just 63 days after sequence identification."
Presumably, those are 5 out of the 8-10 that Gates thinks is promising
[1]: https://cepi.net/news_cepi/cepi-publishes-analysis-of-covid-...
Also because they were quickly able to get 1000+ people for the Phase 1 study, and they're starting the Phase 2/3 study next month (objective: 6000 people recruited).
They want (assuming that it is effective, of course, which is absolutely not guaranteed) to have something ready for emergency use by early autumn.
Perhaps it's just better communication on their part, mind you.
- http://www.ox.ac.uk/news/2020-04-23-oxford-covid-19-vaccine-...
- https://covid19vaccinetrial.co.uk/
- https://www.nytimes.com/2020/04/27/world/europe/coronavirus-...
- https://www.biocentury.com/article/305063/
The NY Times story is a bit of storytelling but it's kind of fascinating how they got there.
For now I'm placing my bets on this one because they do not want royalties out of it and they're seeking deals with many companies to manufacture as much as possible (at risk, because at this point it is not known if it works).